Skip To Main Content
This website is intended exclusively for healthcare professionals residing and/or working in Bahrain.
Campus
Campus

About Type 2 Inflammation – Atopic Dermatitis

The Continuous burden of Atopic Dermatitis can have far-reaching Impact

  • The burden of inadequately controlled atopic dermatitis may become chronic, or even cumulative, impacting patients throughout their lives1,2

~70 - 80% of atopic dermatitis patients develop additional type 2 inflammatory diseases, such as asthma or allergic rhinitis, which correlate with atopic dermatitis severity5,6

*The age of children included in the Eczema Society of Canada Atopic Dermatitis Quality of Life Report survey ranged from 0 to 18 years

~70 - 80% of atopic dermatitis patients develop additional type 2 inflammatory diseases, such as asthma or allergic rhinitis, which correlate with atopic dermatitis severity5,6

* The age of children included in the Eczema Society of Canada Atopic Dermatitis Quality of Life Report survey ranged from 0 to 18 years

~70 - 80% of atopic dermatitis patients develop additional type 2 inflammatory diseases, such as asthma or allergic rhinitis, which correlate with atopic dermatitis severity5,6

* The age of children included in the Eczema Society of Canada Atopic Dermatitis Quality of Life Report survey ranged from 0 to 18 years

References

  1. Zuberbier T et al. J Allergy Clin Immunol 2006; 118:226–232.
  2. Ibler K and Jemec GBE. Dermatol Rep 2011; 31; 3(1):8–10.
  3. Eczema Society of Canada. Atopic Dermatitis Quality of Life Report. 2017.
  4. Stocker RPJ et al. Arch Clin Neuropsychol 2017; 32:349–368.
  5. Davis DM et al. Semin Cutan Med Surg 2017; 36(3):95–99.
  6. Eckert L et al. Global Aware. Report Global 2018.
  7. Holm EA et al. J Eur Acad Dermat Venereol 2006; 20(3):255–259.

Around 3 in 5 adult Moderate-to-Severe Atopic Dermatitis patients are Inadequately controlled despite treatment1*

A chronic, inadequately controlled disease driven by persistent underlying inflammation7,8

Patients may experience intensified disease activity for 30–50% of the year2

 Current treatment paradigm (OCS/ immunosuppressants) primarily addresses disease manifestation using a reactive, episodic approach9

Length of treatment with systemic steroids and other immunosuppressants is limited by common side effects and chance of rebounds11

Continuous treatment of underlying Inflammation is warranted for Long-term disease control10